THTX — Theratechnologies Share Price
0.000.00%
Last trade - 00:00HealthcareAdventurousSmall CapNeutral
- $88.36m
- $125.19m
- $80.06m
- 43
- 46
- 21
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -632.13% | ||
| Return on Equity | n/a | ||
| Operating Margin | -48.85% | ||
Financial Summary
| Year End 30th Nov | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 45.22 | 63.22 | 66.05 | 69.82 | 80.06 | 90.87 | 104.45 | 19.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theratechnologies Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. The Company commercializes two medicines in human immunodeficiency viruses (HIV) and has research programs in non-alcoholic steatohepatitis (NASH), Oncology and HIV. Its medicines include Trogarzo, EGRIFTA SV, and EGRIFTA. Trogarzo (ibalizumab-uiyk) is a monoclonal antibody which binds to domain 2 of the cluster difference 4 (CD4) T cell receptors. In the United States, Trogarzo is developed for the treatment of HIV-1 infection. EGRIFTA SV (tesamorelin for injection) and EGRIFTA are developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Its oncology pipeline includes TH1902 and TH1904. Its Non-alcoholic fatty liver disease (NAFLD) pipeline includes Tesamorelin F8. TH1902 is being evaluated in a Phase I clinical trial.
Directors
- Dawn Svoronos NEC (67)
- Paul Levesque PRE (57)
- Philippe Dubuc CFO (54)
- Christian Marsolais SVP (57)
- Marie-Noel Colussi VFN (51)
- Andre Dupras VPR
- Jocelyn Lafond VPR (52)
- Conor Walshe GMG
- Joseph Arena IND (66)
- Sheila Frame IND (58)
- Frank Holler IND (64)
- Gerald Lacoste IND (77)
- Gary Littlejohn IND (66)
- Andrew Molson IND (53)
- Paul Pommier IND (77)
- Alain Trudeau IND (61)
- Dale Weil IND (65)
- Last Annual
- November 30th, 2022
- Last Interim
- February 28th, 2023
- Incorporated
- February 1st, 1995
- Public Since
- December 21st, 1993
- No. of Employees
- 89
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 97,006,299
- Address
- 2015 Peel Street, 5Th Floor, MONTREAL, H3A 1T8
- Web
- http://www.theratech.com/
- Phone
- +1 5143367800
- Contact
- Elif Mcdonald
- Auditors
- KPMG LLP
Upcoming Events for THTX
Q3 2023 Theratechnologies Inc Earnings Release
Similar to THTX
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Adamis Pharmaceuticals
NASDAQ Capital Market
Affinia Therapeutics
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
FAQ
What is the Theratechnologies share price?
As of Today at 13:22 UTC, shares in Theratechnologies are trading at $0.95. This share price information is delayed by 15 minutes.
How has the Theratechnologies share price performed this year?
Shares in Theratechnologies last closed at $0.95 and the price had moved by -61.38% over the past 365 days. In terms of relative price strength the Theratechnologies share price has underperformed the S&P500 Index by -62.25% over the past year.
What are the analyst and broker recommendations for Theratechnologies?
The overall consensus recommendation for Theratechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Theratechnologies dividend yield?
Theratechnologies does not currently pay a dividend.
Does Theratechnologies pay a dividend?
Theratechnologies does not currently pay a dividend.
When does Theratechnologies next pay dividends?
Theratechnologies does not currently pay a dividend.
How do I buy Theratechnologies shares?
To buy shares in Theratechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theratechnologies?
As of the previous close price of $0.95, shares in Theratechnologies had a market capitalisation of $88.36m.
Where are Theratechnologies shares listed?
Here are the trading details for Theratechnologies:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: THTX
What kind of share is Theratechnologies?
Based on an overall assessment of its quality, value and momentum Theratechnologies is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theratechnologies share price forecast for 2023?
The analyst consensus target price for shares in Theratechnologies is $3.62. That is 281.2% above the last closing price of $0.95.
Analysts covering Theratechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.21 for the next financial year.
What is the trend in the Theratechnologies share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theratechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -58.95%.
As of the last closing price of $0.95, shares in Theratechnologies were trading -32.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theratechnologies PE Ratio?
The Theratechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theratechnologies?
Theratechnologies' management team is headed by:
- Dawn Svoronos - NEC
- Paul Levesque - PRE
- Philippe Dubuc - CFO
- Christian Marsolais - SVP
- Marie-Noel Colussi - VFN
- Andre Dupras - VPR
- Jocelyn Lafond - VPR
- Conor Walshe - GMG
- Joseph Arena - IND
- Sheila Frame - IND
- Frank Holler - IND
- Gerald Lacoste - IND
- Gary Littlejohn - IND
- Andrew Molson - IND
- Paul Pommier - IND
- Alain Trudeau - IND
- Dale Weil - IND